Loading company…
Mythic Therapeutics develops antibody-drug conjugates for cancer treatment.
Founded in 2017 and based in Waltham, US, Mythic Therapeutics develops antibody-drug conjugates designed to deliver chemotherapy to cancer cells. Its FateControl technology is intended to increase drug uptake in malignant cells. In November 2021, the company raised USD 103.10 mn in Series B funding to advance its lung cancer program into first-in-human studies and support pipeline development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in